arrow
W

Wenzhen Ge

Regeneron
H指数:20
被引数:1,451

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

2型炎症性疾病共享共病、分子特征、IL4/IL13遗传学以及对IL4/IL13阻断剂的反应

2026-05-140
OAAI
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States

在美国三药类暴露的复发/难治性多发性骨髓瘤中,林洛塞坦单抗相较于真实世界标准疗法的有效性

2026-04-010
OAAI
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

林伏塞尔塔马布与真实世界国际骨髓瘤工作组三药类暴露的复发/难治性多发性骨髓瘤标准护理的比较

2026-03-250
OAAI
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review

对复发/难治性多发性骨髓瘤预后因素重要性的排序:基于系统文献综述的国际医师专家组共识

2025-04-030
OAAI
Low temperature and temperature decline increase acute aortic dissection risk and burden: A nationwide case crossover analysis at hourly level among 40,270 patients
2022-11-0114
OAAI